Cyclosporine A-Induced Conchal Hyperplasia with Nasal Obstruction in a Patient with Membranous Nephropathy

• Published in: The American journal of case reports Vol. 23; p. e935362
• Main Authors: Tillmann, Frank-Peter, Harth, Ana, Özcan, Fedai, Jörres, Achim
• Format: Journal Article
• Language: English
• Published: United States International Scientific Literature, Inc 21.05.2022
• Subjects: Aged; Cyclosporine - adverse effects; Female; Gingival Hyperplasia - chemically induced; Gingival Hyperplasia - drug therapy; Glomerulonephritis, Membranous - chemically induced; Glomerulonephritis, Membranous - complications; Glomerulonephritis, Membranous - drug therapy; Hirsutism - chemically induced; Hirsutism - drug therapy; Humans; Hyperplasia; Immunosuppressive Agents - adverse effects; Nasal Obstruction; Proteinuria - drug therapy; Turbinates
• ISSN: 1941-5923; 1941-5923
• DOI: 10.12659/AJCR.935362

BACKGROUND The immunomodulatory and pharmacokinetic effects of cyclosporine A are used to treat diverse disease entities in different medical fields, including organ transplantation and/or autoimmune diseases. It is also applied in patients with nephrotic range proteinuria as an adjunct to steroids and supportive antihypertensive/antiproteinuric medications. Cyclosporine has a small therapeutic window and is dosed with respect to the underlying disease entity and severity via trough level adaptations. Among its most frequent adverse effects are hypertension, nephrotoxicity, neurotoxicity, and electrolyte disturbances. Hypertrichosis and gingival hyperplasia are obvious and widely recognized adverse effects. CASE REPORT We report on a 66-year-old woman who was treated with cyclosporine A for primary membranous nephropathy. During treatment with cyclosporine, she developed hirsutism and gingival hyperplasia. Later, she reported having impaired nasal breathing and dyspnea on mild physical exercise. Clinical, rhinoscopic, and radiological evaluations showed marked conchal hyperplasia as a potential cause of her symptoms. An extensive medical work-up did not show evidence of allergic, immunologic, or other drug adverse effects, suggesting cyclosporine-induced hyperplasia of the turbinates as a hypothetical causative factor. Dose reductions did not lead to resolution of symptoms but resulted in increasing proteinuria. Therefore, cyclosporine was stopped, and the patient was treated with rituximab. Thereafter, hirsutism and gingival and conchal hyperplasia gradually regressed over 2-4 months, showing complete resolution of conchal hyperplasia on computed-tomography follow-up after 6 months. CONCLUSIONS Cyclosporine can not only result in gingival hyperplasia but also in hyperplasia of the turbinates leading to impaired nasal breathing and shortness of breath on exertion. An extensive search for many other known causes of conchal swelling is warranted to finally suggest an adverse effect of cyclosporine. Discontinuation of cyclosporine resulted in complete remission of conchal hyperplasia as well as other adverse effects.